The pharmacogenomics of anti-hypertensive therapy

Pharmaceuticals

Volumn 3, Issue 6, 2010, Pages 1779-1791

  Padmanabhan, Sandosh ^a   Paul, Laura ^a   Dominczak, Anna F ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

ACE inhibitors; Angiotensin receptor blockers; Antihypertensive; Beta blockers; Calcium channel blockers; Hypertension; Pharmacogenetics; Pharmacogenomics; Thiazide diuretics

Indexed keywords

ALDOSTERONE SYNTHASE; AMILORIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; APELIN RECEPTOR; BETA 1 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPITHELIAL SODIUM CHANNEL; GLUCOCORTICOID; ORGANIC ANION TRANSPORTER 2; PROTEIN KINASE WNK1; PROTEIN KINASE WNK4; SPIRONOLACTONE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; THIAZIDE DIURETIC AGENT; TRIAMTERENE; UBIQUITIN PROTEIN LIGASE NEDD4;

ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DRUG RESPONSE; ESSENTIAL HYPERTENSION; GENE MAPPING; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HEART OUTPUT; HUMAN; HYPERTENSION; LIDDLE SYNDROME; LOW DRUG DOSE; MONOGENIC DISORDER; PHARMACOGENOMICS; PLASMA RENIN ACTIVITY; REVIEW; SYSTOLIC BLOOD PRESSURE;

EID: 77954938121     PISSN: None     EISSN: 14248247     Source Type: Journal    
DOI: 10.3390/ph3061779     Document Type: Review

References (63)

1. Lewington, S.; Clarke, R.; Qizilbash, N.; Peto, R.; Collins, R. Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002, 360 (9349), 1903-1913.
2. Kearney, P. M.; Whelton, M.; Reynolds, K.; Muntner, P.; Whelton, P. K.; He, J. Global burden of hypertension: analysis of worldwide data. Lancet 2005, 365 (9455), 217-223.
3. Ezzati, M.; Lopez, A. D.; Rodgers, A.; Vander, H. S.; Murray, C. J. Selected major risk factors and global and regional burden of disease. Lancet 2002, 360 (9343), 1347-1360.
4. Hajjar, I.; Kotchen, T. A. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA 2003, 290 (2), 199-206.
5. Lloyd-Jones, D. M.; Evans, J. C.; Larson, M. G.; O'Donnell, C. J.; Roccella, E. J.; Levy, D. Differential control of systolic and diastolic blood pressure: Factors associated with lack of blood pressure control in the community. Hypertension 2000, 36 (4), 594-599.
6. Thoenes, M.; Neuberger, H. R.; Volpe, M.; Khan, B. V.; Kirch, W.; Bohm, M. Antihypertensive drug therapy and blood pressure control in men and women: An international perspective. J. Hum. Hypertens. 2010, 24 (5), 336-344.
7. Cushman, W. C.; Ford, C. E.; Cutler, J. A.; Margolis, K. L.; Davis, B. R.; Grimm, R. H.; Black, H. R.; Hamilton, B. P.; Holland, J.; Nwachuku, C.; Papademetriou, V.; Probstfield, J.; Wright, J. T., Jr.; Alderman, M. H.; Weiss, R. J.; Piller, L.; Bettencourt, J.; Walsh, S. M. Success and predictors of blood pressure control in diverse North American settings: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J. Clin. Hypertens. 2002, 4 (6), 393-404.
8. Canzanello, V. J.; Baranco-Pryor, E.; Rahbari-Oskoui, F.; Schwartz, G. L.; Boerwinkle, E.; Turner, S. T.; Chapman, A. B. Predictors of blood pressure response to the angiotensin receptor blocker candesartan in essential hypertension. Am. J. Hypertens. 2008, 21 (1), 61-66.
9. Blaufox, M. D.; Lee, H. B.; Davis, B.; Oberman, A.; Wassertheil-Smoller, S.; Langford, H. Renin predicts diastolic blood pressure response to nonpharmacologic and pharmacologic therapy. JAMA 1992, 267 (9), 1221-1225.
10. Calhoun, D. A.; Jones, D.; Textor, S.; Goff, D. C.; Murphy, T. P.; Toto, R. D.; White, A.; Cushman, W. C.; White, W.; Sica, D.; Ferdinand, K.; Giles, T. D.; Falkner, B.; Carey, R. M. Resistant hypertension: diagnosis, evaluation, and treatment: A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008, 117 (25), e510-e526.
11. Chapman, A. B.; Schwartz, G. L.; Boerwinkle, E.; Turner, S. T. Predictors of antihypertensive response to a standard dose of hydrochlorothiazide for essential hypertension. Kidney Int. 2002, 61 (3), 1047-1055.
12. Brewster, L. M.; van Montfrans, G. A.; Kleijnen, J. Systematic review: Antihypertensive drug therapy in black patients. Ann. Intern. Med. 2004, 141 (8), 614-627.
13. Johnson, J. A. Ethnic differences in cardiovascular drug response: Potential contribution of pharmacogenetics. Circulation 2008, 118 (13), 1383-1393.
14. Brown, M. J.; Cruickshank, J. K.; Dominiczak, A. F.; MacGregor, G. A.; Poulter, N. R.; Russell, G. I.; Thom, S.; Williams, B. Better blood pressure control: How to combine drugs. J. Hum. Hypertens. 2003, 17 (2), 81-86.
15. Blumenfeld, J. D.; Laragh, J. H. Renin system analysis: A rational method for the diagnosis and treatment of the individual patient with hypertension. Am. J. Hypertens. 1998, 11 (7), 894-896.
16. Laragh, J. H. Renin profiling for diagnosis, risk assessment, and treatment of hypertension. Kidney Int. 1993, 44 (5), 1163-1175.
17. Buhler, F. R.; Bolli, P.; Kiowski, W.; Erne, P.; Hulthen, U. L.; Block, L. H. Renin profiling to select antihypertensive baseline drugs. Renin inhibitors for high-renin and calcium entry blockers for low-renin patients. Am. J. Med. 1984, 77 (2A), 36-42.
18. Laragh, J. H.; Resnick, L. M. Recognizing and treating two types of long-term vasoconstriction in hypertension. Kidney Int. 1988, 25, S162-S174.
19. Williams, B.; Poulter, N. R.; Brown, M. J.; Davis, M.; McInnes, G. T.; Potter, J. F.; Sever, P. S.; Thom, S. M. British Hypertension Society guidelines for hypertension management 2004 (BHS- IV): summary. BMJ 2004, 328 (7440), 634-640.
20. Padmanabhan, S.; Delles, C.; Dominiczak, A. F. Genetic factors in hypertension. Arch. Med. Sci. 2009, 5 (2A), S212-S219.
21. Lifton, R. P.; Dluhy, R. G.; Powers, M.; Rich, G. M.; Gutkin, M.; Fallo, F.; Gill, J. R., Jr.; Feld, L.; Ganguly, A.; Laidlaw, J. C. Hereditary hypertension caused by chimaeric gene duplications and ectopic expression of aldosterone synthase. Nat. Genet. 1992, 2 (1), 66-74.
22. Geller, D. S.; Farhi, A.; Pinkerton, N.; Fradley, M.; Moritz, M.; Spitzer, A.; Meinke, G.; Tsai, F. T.; Sigler, P. B.; Lifton, R. P. Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy. Science 2000, 289 (5476), 119-123.
23. Shimkets, R. A.; Warnock, D. G.; Bositis, C. M.; Nelson-Williams, C.; Hansson, J. H.; Schambelan, M.; Gill, J. R., Jr.; Ulick, S.; Milora, R. V.; Findling, J. W. Liddle's syndrome: Heritable human hypertension caused by mutations in the beta subunit of the epithelial sodium channel. Cell 1994, 79 (3), 407-414.
24. Hansson, J. H.; Nelson-Williams, C.; Suzuki, H.; Schild, L.; Shimkets, R.; Lu, Y.; Canessa, C.; Iwasaki, T.; Rossier, B.; Lifton, R. P. Hypertension caused by a truncated epithelial sodium channel gamma subunit: Genetic heterogeneity of Liddle syndrome. Nat. Genet. 1995, 11 (1), 76-82.
25. Wilson, F. H.; Disse-Nicodeme, S.; Choate, K. A.; Ishikawa, K.; Nelson-Williams, C.; Desitter, I.; Gunel, M.; Milford, D. V.; Lipkin, G. W.; Achard, J. M.; Feely, M. P.; Dussol, B.; Berland, Y.; Unwin, R. J.; Mayan, H.; Simon, D. B.; Farfel, Z.; Jeunemaitre, X.; Lifton, R. P. Human hypertension caused by mutations in WNK kinases. Science 2001, 293 (5532), 1107-1112.
26. Carretero, O. A.; Oparil, S. Essential hypertension. Part I: Definition and etiology. Circulation 2000, 101 (3), 329-335.
27. Luft, F. C. Twins in cardiovascular genetic research. Hypertension 2001, 37 (2), 350-356.
28. Mongeau, J. G.; Biron, P.; Sing, C. F. The influence of genetics and household environment upon the variability of normal blood pressure: The Montreal Adoption Survey. Clin. Exp. Hypertens. 1986, 8 (4&5), 653-660.
29. Cowley, A. W., Jr. The genetic dissection of essential hypertension. Nat. Rev. Genet. 2006, 7 (11), 829-840.
30. Gu, C. C.; Hunt, S. C.; Kardia, S.; Turner, S. T.; Chakravarti, A.; Schork, N.; Olshen, R.; Curb, D.; Jaquish, C.; Boerwinkle, E.; Rao, D. C. An investigation of genome-wide associations of hypertension with microsatellite markers in the family blood pressure program (FBPP). Hum. Genet. 2007, 121 (5), 577-590.
31. Caulfield, M.; Munroe, P.; Pembroke, J.; Samani, N.; Dominiczak, A.; Brown, M.; Benjamin, N.; Webster, J.; Ratcliffe, P.; O'Shea, S.; Papp, J.; Taylor, E.; Dobson, R.; Knight, J.; Newhouse, S.; Hooper, J.; Lee, W.; Brain, N.; Clayton, D.; Lathrop, G. M.; Farrall, M.; Connell, J. Genome-wide mapping of human loci for essential hypertension. Lancet 2003, 361 (9375), 2118-2123.
32. Padmanabhan, S.; Wallace, C.; Munroe, P. B.; Dobson, R.; Brown, M.; Samani, N.; Clayton, D.; Farrall, M.; Webster, J.; Lathrop, M.; Caulfield, M.; Dominiczak, A. F.; Connell, J. M. Chromosome 2p shows significant linkage to antihypertensive response in the British Genetics of Hypertension Study. Hypertension 2006, 47 (3), 603-608.
33. Barkley, R. A.; Chakravarti, A.; Cooper, R. S.; Ellison, R. C.; Hunt, S. C.; Province, M. A.; Turner, S. T.; Weder, A. B.; Boerwinkle, E. Positional identification of hypertension susceptibility genes on chromosome 2. Hypertension 2004, 43 (2), 477-482.
34. Padmanabhan, S.; Melander, O.; Hastie, C.; Menni, C.; Delles, C.; Connell, J. M.; Dominiczak, A. F. Hypertension and genome-wide association studies: Combining high fidelity phenotyping and hypercontrols. J. Hypertens. 2008, 26 (7), 1275-1281.
35. Arnett, D. K.; Davis, B. R.; Ford, C. E.; Boerwinkle, E.; Leiendecker-Foster, C.; Miller, M. B.; Black, H.; Eckfeldt, J. H. Pharmacogenetic association of the angiotensin-converting enzyme insertion/deletion polymorphism on blood pressure and cardiovascular risk in relation to antihypertensive treatment: The Genetics of Hypertension-Associated Treatment (GenHAT) study. Circulation 2005, 111 (25), 3374-3383.
36. Brunner, M.; Cooper-DeHoff, R. M.; Gong, Y.; Karnes, J. H.; Langaee, T. Y.; Pepine, C. J.; Johnson, J. A. Factors influencing blood pressure response to trandolapril add-on therapy in patients taking verapamil SR (from the International Verapamil SR/Trandolapril [INVEST] Study). Am. J. Cardiol. 2007, 99 (11), 1549-1554.
37. Turner, S. T.; Schwartz, G. L.; Chapman, A. B.; Boerwinkle, E. WNK1 kinase polymorphism and blood pressure response to a thiazide diuretic. Hypertension 2005, 46 (4), 758-765.
38. Arnett, D. K.; Claas, S. A.; Lynch, A. I. Has pharmacogenetics brought us closer to 'personalized medicine' for initial drug treatment of hypertension? Curr. Opin. Cardiol. 2009, 24 (4), 333-339.
39. Pacanowski, M. A.; Gong, Y.; Cooper-DeHoff, R. M.; Schork, N. J.; Shriver, M. D.; Langaee, T. Y.; Pepine, C. J.; Johnson, J. A. beta-adrenergic receptor gene polymorphisms and beta-blocker treatment outcomes in hypertension. Clin. Pharmacol. Ther. 2008, 84 (6), 715-721.
40. Lemaitre, R. N.; Heckbert, S. R.; Sotoodehnia, N.; Bis, J. C.; Smith, N. L.; Marciante, K. D.; Hindorff, L. A.; Lange, L. A.; Lumley, T. S.; Rice, K. M.; Wiggins, K. L.; Psaty, B. M. beta1- and beta2-adrenergic receptor gene variation, beta-blocker use and risk of myocardial infarction and stroke. Am. J. Hypertens. 2008, 21 (3), 290-296.
41. Johnson, J. A.; Zineh, I.; Puckett, B. J.; McGorray, S. P.; Yarandi, H. N.; Pauly, D. F. Beta 1- adrenergic receptor polymorphisms and antihypertensive response to metoprolol. Clin. Pharmacol. Ther. 2003, 74 (1), 44-52.
42. Liu, J.; Liu, Z. Q.; Yu, B. N.; Xu, F. H.; Mo, W.; Zhou, G.; Liu, Y. Z.; Li, Q.; Zhou, H. H. beta1- Adrenergic receptor polymorphisms influence the response to metoprolol monotherapy in patients with essential hypertension. Clin. Pharmacol. Ther. 2006, 80 (1), 23-32.
43. Psaty, B. M.; Smith, N. L.; Heckbert, S. R.; Vos, H. L.; Lemaitre, R. N.; Reiner, A. P.; Siscovick, D. S.; Bis, J.; Lumley, T.; Longstreth, W. T., Jr.; Rosendaal, F. R. Diuretic therapy, the alphaadducin gene variant, and the risk of myocardial infarction or stroke in persons with treated hypertension. JAMA 2002, 287 (13), 1680-1689.
44. Davis, B. R.; Arnett, D. K.; Boerwinkle, E.; Ford, C. E.; Leiendecker-Foster, C.; Miller, M. B.; Black, H.; Eckfeldt, J. H. Antihypertensive therapy, the alpha-adducin polymorphism, and cardiovascular disease in high-risk hypertensive persons: The Genetics of Hypertension- Associated Treatment Study. Pharmacogenomics J. 2007, 7 (2), 112-122.
45. Gerhard, T.; Gong, Y.; Beitelshees, A. L.; Mao, X.; Lobmeyer, M. T.; Cooper-DeHoff, R. M.; Langaee, T. Y.; Schork, N. J.; Shriver, M. D.; Pepine, C. J.; Johnson, J. A. Alpha-adducin polymorphism associated with increased risk of adverse cardiovascular outcomes: Results from GENEtic Substudy of the INternational VErapamil SR-trandolapril STudy (INVEST-GENES). Am. Heart J. 2008, 156 (2), 397-404.
46. Manunta, P.; Lavery, G.; Lanzani, C.; Braund, P. S.; Simonini, M.; Bodycote, C.; Zagato, L.; Delli, C. S.; Tantardini, C.; Brioni, E.; Bianchi, G.; Samani, N. J. Physiological interaction between alpha-adducin and WNK1-NEDD4L pathways on sodium-related blood pressure regulation. Hypertension 2008, 52 (2), 366-372.
47. De Buyzere, M. Selective genetic advantages for users of thiazide diuretics. Is there a case for the 460Trp variant of alpha-adducin? J. Hypertens. 2009, 27 (1), 24-27.
48. Kelley-Hedgepeth, A.; Peter, I.; Kip, K.; Montefusco, M.; Kogan, S.; Cox, D.; Ordovas, J.; Levy, D.; Reis, S.; Mendelsohn, M.; Housman, D.; Huggins, G. The protective effect of KCNMB1 E65K against hypertension is restricted to blood pressure treatment with beta-blockade. J. Hum. Hypertens. 2008, 22 (7), 512-515.
49. Beitelshees, A. L.; Gong, Y.; Wang, D.; Schork, N. J.; Cooper-DeHoff, R. M.; Langaee, T. Y.; Shriver, M. D.; Sadee, W.; Knot, H. J.; Pepine, C. J.; Johnson, J. A. KCNMB1 genotype influences response to verapamil SR and adverse outcomes in the INternational VErapamil SR/Trandolapril STudy (INVEST). Pharmacogenet. Genomics 2007, 17 (9), 719-729.
50. Turner, S. T.; Bailey, K. R.; Fridley, B. L.; Chapman, A. B.; Schwartz, G. L.; Chai, H. S.; Sicotte, H.; Kocher, J. P.; Rodin, A. S.; Boerwinkle, E. Genomic association analysis suggests chromosome 12 locus influencing antihypertensive response to thiazide diuretic. Hypertension 2008, 52 (2), 359-365.
51. Kurland, L.; Lind, L.; Melhus, H. Using genotyping to predict responses to anti-hypertensive treatment. Trends Pharmacol. Sci. 2005, 26 (9), 443-447.
52. Link, E.; Parish, S.; Armitage, J.; Bowman, L.; Heath, S.; Matsuda, F.; Gut, I.; Lathrop, M.; Collins, R. SLCO1B1 variants and statin-induced myopathy-A genomewide study. N. Engl. J. Med. 2008, 359 (8), 789-799.
53. Eichler, E. E.; Flint, J.; Gibson, G.; Kong, A.; Leal, S. M.; Moore, J. H.; Nadeau, J. H. Missing heritability and strategies for finding the underlying causes of complex disease. Nat. Rev. Genet 2010, 11 (6), 446-450.
54. Cantor, R. M.; Lange, K.; Sinsheimer, J. S. Prioritizing GWAS results: A review of statistical methods and recommendations for their application. Am. J. Hum. Genet 2010, 86 (1), 6-22.
55. Chanock, S. J.; Manolio, T.; Boehnke, M.; Boerwinkle, E.; Hunter, D. J.; Thomas, G.; Hirschhorn, J. N.; Abecasis, G.; Altshuler, D.; Bailey-Wilson, J. E.; Brooks, L. D.; Cardon, L. R.; Daly, M.; Donnelly, P.; Fraumeni, J. F., Jr.; Freimer, N. B.; Gerhard, D. S.; Gunter, C.; Guttmacher, A. E.; Guyer, M. S.; Harris, E. L.; Hoh, J.; Hoover, R.; Kong, C. A.; Merikangas, K. R.; Morton, C. C.; Palmer, L. J.; Phimister, E. G.; Rice, J. P.; Roberts, J.; Rotimi, C.; Tucker, M. A.; Vogan, K. J.; Wacholder, S.; Wijsman, E. M.; Winn, D. M.; Collins, F. S. Replicating genotype-phenotype associations. Nature 2007, 447 (7145), 655-660.
56. Padmanabhan, S.; Menni, C.; Lee, W. K.; Laing, S.; Brambilla, P.; Sega, R.; Perego, R.; Grassi, G.; Cesana, G.; Delles, C.; Mancia, G.; Dominiczak, A. F. The effects of sex and method of blood pressure measurement on genetic associations with blood pressure in the PAMELA study. J. Hypertens. 2010, 28 (3), 465-477.
57. Pickering, T. G.; Hall, J. E.; Appel, L. J.; Falkner, B. E.; Graves, J.; Hill, M. N.; Jones, D. W.; Kurtz, T.; Sheps, S. G.; Roccella, E. J. Recommendations for blood pressure measurement in humans and experimental animals: part 1: Blood pressure measurement in humans: A statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Circulation 2005, 111 (5), 697-716.
58. Trazzi, S.; Mutti, E.; Frattola, A.; Imholz, B.; Parati, G.; Mancia, G. Reproducibility of noninvasive and intra-arterial blood pressure monitoring: implications for studies on antihypertensive treatment. J. Hypertens. 1991, 9 (2), 115-119.
59. Mancia, G.; Parati, G.; Pomidossi, G.; Grassi, G.; Casadei, R.; Zanchetti, A. Alerting reaction and rise in blood pressure during measurement by physician and nurse. Hypertension 1987, 9 (2), 209-215.
60. Andersen, U. O.; Henriksen, J. H.; Jensen, G. Sources of measurement variation in blood pressure in large-scale epidemiological surveys with follow-up. Blood Press 2002, 11 (6), 357-365.
61. Dasgupta, K.; O'Loughlin, J.; Chen, S.; Karp, I.; Paradis, G.; Tremblay, J.; Hamet, P.; Pilote, L. Emergence of sex differences in prevalence of high systolic blood pressure: Analysis of a longitudinal adolescent cohort. Circulation 2006, 114 (24), 2663-2670.
62. Hardy, R.; Kuh, D.; Whincup, P. H.; Wadsworth, M. E. Age at puberty and adult blood pressure and body size in a British birth cohort study. J. Hypertens. 2006, 24 (1), 59-66.
63. Seda, O.; Tremblay, J.; Gaudet, D.; Brunelle, P. L.; Gurau, A.; Merlo, E.; Pilote, L.; Orlov, S. N.; Boulva, F.; Petrovich, M.; Kotchen, T. A.; Cowley, A. W., Jr.; Hamet, P. Systematic, genomewide, sex-specific linkage of cardiovascular traits in French Canadians. Hypertension 2008, 51 (4), 1156-1162.